Characteristics of thawed pooled cryoprecipitate stored at refrigerated temperature for 24 hours

被引:13
作者
Soundar, Esther P. [1 ]
Reyes, Meredith [1 ]
Korte, Laura [1 ]
Bracey, Arthur [1 ]
机构
[1] Baylor Coll Med, Dept Pathol, Baylor St Lukes Med Ctr, CHI St Lukes Hlth, MC 4-265,POB 20345, Houston, TX 77225 USA
关键词
fibrinogen; factor VIII; von Willebrand factor; FRESH-FROZEN PLASMA; FIBRINOGEN REPLACEMENT THERAPY;
D O I
10.2450/2017.0133-17
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The need for thawed cryoprecipitate is growing. However, according to current guidelines, the shelf-life of pooled thawed cryoprecipitate at room temperature is limited because of possible bacterial contamination and loss of clotting factor activity. Here we assessed microbial growth and retention of clotting activity in cryoprecipitate stored at 4 degrees C after thawing to see whether its shelf life could be safely extended. Materials and methods. Pooled thawed cryoprecipitate units (n=10) were maintained at room temperature for 6 hours and then placed at 1-6 degrees C for 18 hours after thawing. We examined the cryoprecipitate pools for fibrinogen, factor VIII, and von Willebrand factor activity at the following time points: 0 hours (immediately after thawing), after 6 hours at room temperature, and after 24 hours at 1-6 degrees C. A 5-mL aliquot from each pool was collected for aerobic and anaerobic bacterial cultures at the 24-hour time point. Results. Mean fibrinogen concentration and von Willebrand factor activity were similar at each time point, but factor VIII activity decreased significantly over the storage period. Bacterial growth was not detected in any cultured pooled sample. Discussion. Extended storing of thawed cryoprecipitate at 1-6 degrees C does not appear to increase the risk of bacterial contamination or affect coagulation factor activity.
引用
收藏
页码:443 / 446
页数:4
相关论文
共 20 条
  • [1] AABB America's Blood Centers American Red Cross Armed Services Blood Program, CIRC INF US HUM BLOO
  • [2] [Anonymous], 2016, TRANSFUSION SS4, V56, p3A
  • [3] Australian & New Zealand Society of Blood Transfusion Ltd, EXT LIF PLASM FRAM P
  • [4] Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw
    Bhakta, Varsha
    Jenkins, Craig
    Ramirez-Arcos, Sandra
    Sheffield, William P.
    [J]. TRANSFUSION, 2014, 54 (02) : 418 - 425
  • [5] Bacterial contamination of blood components
    Brecher, ME
    Hay, SN
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (01) : 195 - +
  • [6] Casewell M W, 1981, J Hosp Infect, V2, P237, DOI 10.1016/0195-6701(81)90043-8
  • [7] Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma
    Caudill, Jonathan S. C.
    Nichols, William L.
    Plumhoff, Elizabeth A.
    Schulte, Sandra L.
    Winters, Jeffrey L.
    Gastineau, Dennis A.
    Rodriguez, Vilmarie
    [J]. TRANSFUSION, 2009, 49 (04) : 765 - 770
  • [8] Fibrinogen replacement therapy: a critical review of the literature
    Franchini, Massimo
    Lippi, Giuseppe
    [J]. BLOOD TRANSFUSION, 2012, 10 (01) : 23 - 27
  • [9] The hemostatic properties of thawed pooled cryoprecipitate up to 72 hours
    Green, Laura
    Backholer, Lucy
    Wiltshire, Mike
    Platton, Sean
    Stanworth, Simon J.
    Cardigan, Rebecca
    [J]. TRANSFUSION, 2016, 56 (06) : 1356 - 1361
  • [10] How I use fibrinogen replacement therapy in acquired bleeding
    Levy, Jerrold H.
    Goodnough, Lawrence T.
    [J]. BLOOD, 2015, 125 (09) : 1387 - 1393